Healthcare provisions in the Inflation Reduction Act
What’s changing for Medicare plans, pharmaceutical manufacturers, and other healthcare stakeholders?
An overview of the new healthcare regulations
WHITE PAPER
Lessons from the first drugs chosen for Medicare price negotiation
The Inflation Reduction Act requires drug manufacturers to negotiate prices with the federal government, a change with wide-ranging implications for the pharmaceutical industry and healthcare payers.
View the paperWEBINAR
The Inflation Reduction Act's key reforms
Get an overview of the law's main changes to Medicare and other healthcare markets, and a timeline for implementation.
Watch the webinar
Insight
Indirect impacts of the Inflation Reduction Act benefit redesign on Medicare Part D
We reflect on the redesigned Medicare Part D benefit under the Inflation Reduction Act, including shortfalls in funding mechanics and potential adjustments.
Medicare drug price negotiation: Navigating the next wave of maximum fair prices
Deeper discounts in the latest round of negotiated prices for Medicare Part D drugs may indicate how future negotiations will play out.
Medicare drug price negotiation: New dynamics as the tide turns to Medicare Part B
Medicare drug price negotiation: With the first cycle where Part B drugs are eligible to be selected, the implications extend far beyond simple price reductions.
4 key takeaways from the third round of drugs selected for Medicare drug price negotiation
The Centers for Medicare and Medicaid Services announced the list of drugs selected for price negotiation for 2028. We broke down the implications.
Medicare drug price negotiation: Navigating the next wave of maximum fair prices
Deeper discounts in the latest round of negotiated prices for Medicare Part D drugs may indicate how future negotiations will play out.
340B Rebate Model Pilot Program—Medicaid implications and considerations
What state Medicaid programs should know and do ahead of the January 2026 launch
The evolution of biosimilars in the United States
Biosimilars recently have made significant strides toward greater acceptance and utilization since their first U.S. approval in 2015, although challenges persist.
Out of whose pocket? Many beneficiaries will spend less than expected to reach the IRA’s new $2,000 out-of-pocket spending limit
We dive into ramifications of the Inflation Reduction Act on out-of-pocket spending limits for health insurance markets and Medicare Part D.
Navigating new waters: How the Inflation Reduction Act alters government funding for Medicare Part D
The 2025 national average Part D direct subsidy (DS) will increase to $142.67 as plan sponsors take on additional Part D risk in 2025.
A prescription for change: How the 2025 Medicare Part D risk adjustment (RxHCC) model overhaul will affect risk scores
Medicare Advantage organizations (MAOs) will experience another material model change in 2025—this time for Part D.
Preparing for the next Medicare bid cycle
Related Milliman services
Recommended for you
Milliman MACVAT (Medicare Advantage Competitive Value Added Tool)
